About us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting.

The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company’s shares are listed on AktieTorget (ATORG:SEZI).

Press releases

Publication of prospectus regarding the rights issue in Senzime and application for listing on Nasdaq First North

Uppsala, March 14, 2017. The Board of Senzime AB (publ) ("Senzime") has prepared a prospectus regarding the rights issue that was resolved at the extraordinary general meeting in Senzime on March 3, 2017. The Board of Senzime has also applied for listing on Nasdaq First North, and the first day of trading on Nasdaq First North is expected to be April 11, 2017.

Read more

Bulletin from the Extraordinary General Meeting in Senzime AB (publ) – resolution on new issue of shares

The shareholders of Senzime have at the Extraordinary General Meeting on March 3, 2017 resolved, in accordance with the board's proposal, to issue new shares with pre-emption rights for existing shareholders. 

Read more

Notice of Extraordinary General Meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9.30 (local time) on Friday 3 March 2017 in the premises of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

Read more
See all »

News

Preliminary results to be presented at IARS 2017

Uppsala, March 13, 2017. Senzime AB (publ) is happy to announce that the abstract authored by Dr. J. Ross Renew from the Mayo Clinic and entitled, “Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor” was accepted for publication. The volunteer study compared the TetraGraph and TOF-Watch, and the results will be presented at IARS (International Anesthesia Research Society) 2017 Annual Meeting and International Science Symposium, in Washington DC, May 6-9.

Read more

Senzime AB (publ) launches new website

Read more

Senzime in the news- Needle-free probe provides information on how organs and tissues recover after surgery

Uppsala BIO and BIO-X writes about Senzime in their news. Senzime has developed an integrated monitoring system that can provide information on the state of a body’s organs. A probe (OnZurf Probe) placed on the tissue surface collects a microdialysis sample that is read by an instrument (CliniSenz Analyzer). Senzime is one of the companies that received funding in the BIO-X call ‘New diagnostic solutions for disease monitoring’.

Read more
See all »